TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Emergence of resistant bacteria
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Change in Cerebral Blood Flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total Piritramide consumption
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of patients prematurely discontinuing TTFields due to Skin Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of hereditary cerebellar ataxia
Endpoint domain: Mortality/survival
Primary endpoint: Vascular access success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Plasma concentration of primaquine and carboyprimaquine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intestinal microbiome composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intestinal Fatty Acid Binding Protein (IFABP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Jebsen-Taylor Hand Function Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Motor Activity Log Rating Scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Visual Analogue Scale for Anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Blastocyst development rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Proportion of patients experiencing first unprovoked seizures
Endpoint domain: Adverse events/effects
Primary endpoint: Hematological parameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: clinical cure rates based on resolution of infection-related signs and symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: minimally to moderately infective dose (MMID) of influenza A H3N2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Total and cause specific mortality
Endpoint domain: Mortality/survival
Primary endpoint: Any Surgical-site Infection
Endpoint domain: Adverse events/effects
Primary endpoint: Molecular differences
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical flare
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serological flare
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cessation of convulsions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Knowledge about child abuse diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knowledge about child abuse reporting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Attitude and practice towards child abuse
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Prevention of exercise-induced asthma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Humoral and cellular immune responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Xrays evolution at 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in joint range of motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Changes in muscle strength of quadriceps, the gastrocnemius and biceps
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Identification and quantification of vaginal flora anomalies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence or intensity of PONV
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in Crohn's Disease Activity Index (CDAI) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Impedance change from first to last measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Plasma Catecholamine Levels (Maximum Concentration, Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Catecholamine Levels (Time to Maximum Concentration, Tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Catecholamine Levels (Maximum Concentration, Area-under-curve (AUC))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of progression-free patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patients overall experience of IUD insertion
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Average Daily Total Combined Rhinitis Symptom and Medication Score (TCRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brain activation associated with decision-making
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Virologic efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Equivalence of RCM determination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Treated With Chemotherapy in First Line Therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of Participants Treated With Other Therapies in First Line Therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of Participants Treated With Chemotherapy in Second Line Therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of Participants Treated With Other Therapies in Second Line Therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Area Under Plasma Concentration Time Curve From Time Zero to the Last Quantifiable (AUC [0-last])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease Control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of any cause mortality
Endpoint domain: Mortality/survival
Primary endpoint: hospitalization secondary to cardiovascular cause
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in proportion of subjects who experience a major amputation
Endpoint domain: Mortality/survival
Primary endpoint: Reduction in proportion of subjects who die within 6 months from treatment initiation
Endpoint domain: Mortality/survival
Primary endpoint: Bone Material Strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone Indentation Distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sustained 4-week Smoking Abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of imipenem administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Risk for Venous Thromboembolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change in Glycosylated Hemoglobin (HbA1c) Across Age Categories
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Glycosylated Hemoglobin (HbA1c) Across Renal Function Categories
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pharmacokinetic properties of lorcaserin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of subjects with vaccine take
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of condom protected vaginal sex acts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number, severity and type of treatment emergent adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Triglyceride/HDL-C ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: EUS performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with Omphalocele
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with omphaloceles and associated malformations, especially pulmonary hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Two-years outcome
Endpoint domain: Mortality/survival
Primary endpoint: Serum concentrations of alirocumab SAR236553
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in score difference
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 3 years relapse-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Amount of all procedural related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Amount of treatment related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients with PAH worsening and all cause death events
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of serious adverse device effects
Endpoint domain: Adverse events/effects
Primary endpoint: All death including cardiac and non cardiac death
Endpoint domain: Mortality/survival
Primary endpoint: Any revascularizations (TLR or TVR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change of Nuclear area size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree of gut cleansing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Overall quality of colonic cleansing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Physicians overall judgement of colon preparation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of labeled cardiomyocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from Baseline in Pseudomonas aeruginosa abundance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in Clinician Administered PTSD Scale Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Self-Injurious Thoughts and Behaviors Interview Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change physical and mental health assessed by Military Suicide Research Consortium Common Data Elements
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percentage of Participants Achieving Target RDI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Visual Analog Score (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Unified Parkinson's Disease Rating Scale (UPDRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Unified Parkinson's Disease Rating Scale Part III (UPDRSIII)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Patient ON-OFF diary recording
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: parameters of oxidative stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety Measure
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Adverse Effects as Assessed by CTCAE v 3.0
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Seroprotected Subjects With Anti-diphteria (Anti-D) and Anti-tetanus (Anti-T) Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Seropositive Subjects With Anti-tetanus (Anti-T) Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Entrustable Professional Activities
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Changes in Fasting Glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Sleep Duration Change
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Changes in Mood
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in Sleep
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: cMRI image quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean microbial diversity of the vaginal and gut microbiota
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intravenous antibiotic-free day within 14 days
Endpoint domain: Adverse events/effects
Primary endpoint: Patient adherence to action plan
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Acceptability of the Intervention Measured by the Study Visit Satisfaction Form
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pain and Walking Ability Determined by a Merle d' Aubigné Score Increase of >4 Points
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Implant Survival Measured by the Number of Revisions
Endpoint domain: Mortality/survival
Primary endpoint: WOMAC Score Value Decrease at 2-years in Min. 25 Points Compared to the Pre-operative WOMAC Score Value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Self-Reported Preference for Opioid Pain Reliever
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in patient balance parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Mean Cartilage Thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Knee Pain Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximum observed plasma concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Observed terminal elimination half-life (T1/2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 10 metres walk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absence of Middle Ear Fluid by Pneumatic Otoscopy, Right Ear
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ear outcomes
Primary endpoint: Absence of Middle Ear Fluid by Pneumatic Otoscopy, Left Ear
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ear outcomes
Primary endpoint: stroke-related neurologic death or major ipsilateral or disabling stroke
Endpoint domain: Mortality/survival
Primary endpoint: adequate aneurysm occlusion without retreatment or significant parent artery stenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of reported Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Influence on patients subjective well-being
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: serum sex hormone levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Urine Total NNAL Amount Excreted (ng/24 Hour)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urine Total NNAL Amount Excreted Percent Change From Baseline (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Attraction to violence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Self-committed violence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SPID24 (VAS pain/soreness on movement)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immediate change in Neurocognitive function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Longterm change in Neurocognitive function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Functional capacity using six minute walk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distance of six minute walk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neurologic Complication Rate
Endpoint domain: Adverse events/effects
Primary endpoint: Identification of new tumour lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Time from food intake to mix of food in the gut with bile acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percentage of orally ingested exogenic bile acid retained in the body after 7 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline in I-V Interwave Latency on BAEP (Right Side)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change From Baseline in I-V Interwave Latency on BAEP (Left Side)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Subchondral microfracture of tibia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in concentration of total mutant circulating DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in proportion of mutant circulating DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in integrity index of circulating DNA for ACTB gene
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in integrity index of circulating DNA for KRAS gene
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glucose metabolism disturbance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Numeric Pain Intensity Rating Scale (NPRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Faces Pain Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measurement of sedation and analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hematopoietic engraftment kinetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Efficacy at week 48
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients With at Least One Treatment Emergent Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Confirmed Undetectable Plasma Cytomegalovirus (CMV) Within 6 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of Participants With a Treatment Emergent Adverse Event (TEAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Serum brain-derived neurotrophic factor concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Rate of bacterial infections
Endpoint domain: Adverse events/effects
Primary endpoint: Skindex survey results
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of Participants Completing 90-Day Follow-Up
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of Participants Requiring One or More Hypoglycemia Treatments
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Pre-specified Adverse Events Associated With Glyburide According to Protocol
Endpoint domain: Adverse events/effects
Primary endpoint: Patient self-reported intention to take medication
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants With Treatment Emergent Treatment-Related Adverse Event(s)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Laboratory Test Findings of Potential Clinical Importance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Electrocardiogram (ECG) Findings of Potential Clinical Importance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Patient Responsiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diabetes Distress Scale score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Fluorescent signal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sedation Quality
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction in Fluoroscopy Exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Location of the thrombus within the lungs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Location of clot burden measurements within the thigh
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Assessment of 64Cu-FBP8 fibrin activity in the pelvic and upper extremity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Participants With Adverse Events by Severity
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Change From Baseline in Albumin and Total Protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes